Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review.
10.7534/j.issn.1009-2137.2019.06.051
- Author:
Dong-Liang XU
1
;
Zi-Qian LI
1
;
Ge ZHANG
2
Author Information
1. Department of Microbiology and biochemical Pharmacy, College of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510006, Guangdong Province, China.
2. Department of Microbiology and biochemical Pharmacy, College of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510006, Guangdong Province, China,E-mail: zhangge@mail.sysu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
Apoptosis;
B7-H1 Antigen;
Humans;
Lymphoma;
Programmed Cell Death 1 Receptor
- From:
Journal of Experimental Hematology
2019;27(6):2019-2023
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Tumor cells avoid immune surveillance by overexpressing ligands of checkpoint receptors on tumor cells or adjacent cells, resulting in inability or exhaustion of T cells. Numerous studies have shown that lymphoma cells highly expressed programmed cell death ligand-1 (PD-L1), suggesting that PD-1 may become an important target for lymphoma treatment. By targeting the PD-1 protein, the cellular activity of T cells will be significantly enhanced, and the tumor growth will be inhibited. Recently, antibodies against PD-1 have shown high efficacy and safety in the clinical studies of lymphoma, which are expected to become the targeted therapeutic drugs for lymphoma. In order to deeply understand the application of PD-1 antibody in treatment of lymphoma, this review briefly summaries the present state of lymphoma studies, the action mechanism and preparation method of PD-1 antibody in clinical treatment of lymphoma.
